Category Archives: Transhuman News

Over the past few years, Professor Zhang Yongzhen has made it his business to sequence thousands of previously unknown viruses. But he knew straight away that this one was particularly nasty. It was about 1:30 p.m. on Jan. 3 that a metal box arrived at the drab, beige buildings that house the Shanghai Public Health Clinical Center. Inside was a test tube packed in dry ice that contained swabs from a patient suffering from a peculiar pneumonia sweeping Chinas central city of Wuhan. But little did Zhang know that that box would also unleash a vicious squall of blame and geopolitical acrimony worthy of Pandora herself. Now, he is seeking to set the record straight.

Zhang and his team set to work, analyzing the samples using the latest high-throughput sequencing technology for RNA, the viral genetic building blocks, which function similar to how DNA works in humans. By 2 a.m. on Jan. 5, after toiling through two nights straight, they had mapped the first complete genome of the virus that has now sickened 23 million and killed 810,000 across the globe: SARS-CoV-2. It took us less than 40 hours, so very, very fast, Zhang tells TIME in an exclusive interview. Then I realized that this virus is closely related to SARS, probably 80%. So certainly, it was very dangerous.

The events that followed Zhangs discovery have since become swathed in controversy. Crises beget scapegoats and the coronavirus is no different. The floundering U.S. response to the pandemic has prompted a wave of racially tinged soundbites, such as China virus and Kung Flu, as President Donald Trumps Administration seeks to divert blame onto the nation where the pathogen was first identified. The outbreak of COVID angered many people in the Administration and presented an election issue for President Trump, Ambassador Jeffrey Bader, formerly President Obamas chief adviser on Asia, said at a recent meeting of the Foreign Correspondents Club of China.

Read more: Inside the Global Quest to Trace the Origins of COVID-19and Predict Where It Will Go Next

Upon first obtaining the genome, Zhang says he immediately called Dr. Zhao Su, head of respiratory medicine at Wuhan Central Hospital, to request the clinical data of the relevant patient. I couldnt say it was more dangerous than SARS, but I told him it was certainly more dangerous than influenza or Avian flu H5N1, says Zhang. He then contacted Chinas Ministry of Health and traveled to Wuhan, where he spoke to top public health officials over dinner Jan. 8. I had two judgements: first that it was a SARS-like virus; second, that the virus transmits by the respiratory tract. And so, I had two suggestions: that we should take some emergency public measures to protect against this disease; also, clinics should develop antiviral treatments.

Afterward, Zhang returned to Shanghai and prepared to travel to Beijing for more meetings. On the morning of Jan. 11, he was on the runway at Shanghai Hongqiao Airport when he received a phone call from a colleague, Professor Edward Holmes at the University of Sydney. A few minutes later, Zhang was strapped in for takeoff and still on the phonethen Holmes asked permission to release the genome publicly. I asked Eddie to give me one minute to think, Zhang recalls. Then I said ok. For the next two hours, Zhang was cocooned from the world at 35,000 feet, but Holmes post on the website Virological.org sent shockwaves through the global scientific community.

By the time Zhang touched down in Beijing, his discovery was headline news. Officials swooped on his laboratory to demand an explanation. Maybe they couldnt understand how we obtained the genome sequence so fast, says Zhang. Maybe they didnt fully believe our genome. So, I think its normal for the authorities to check our lab, our protocols.

Read more: China Says Its Beating Coronavirus. But Can We Believe Its Numbers?

Critics of Chinas response have latched onto the Jan. 11 date of publication as evidence of a cover-up: why, they ask, didnt Zhang publish it on Jan. 5, when he first finished the sequencing? Also, Zhangs lab was probed by Chinese authorities for rectification, an obscure term to imply some malfeasance. To many observers, it seemed that furious officials scrambling to snuff out evidence of the outbreak were punishing Zhang simply for sharing the SARS-CoV-2 genomeand in the meanwhile, slowing down the release of this key information.

Yet Zhang denies reports in Western media that his laboratory suffered any prolonged closure, and instead says it was working furiously during the early days of the outbreak. From late January to April, we screened more than 30,000 viral samples, says Fan Wu, a researcher who assisted Zhang with the first SARS-CoV-2 sequencing.

And, in fact, Zhang insists he first uploaded the genome to the U.S. National Center for Biotechnology Information (NCBI) on Jan. 5an assertion corroborated by the submission date listed on the U.S government institutions Genbank. When we posted the genome on Jan. 5, the United States certainly knew about this virus, he says. But it can take days or even weeks for the NCBI to look at a submission, and given the gravity of the situation and buoyed by the urging of colleagues, Zhang chose to expedite its release to the public, by publishing it online. (Approached by TIME, Holmes deferred to Zhangs version of events.) Its a decision that facilitated the swift development of testing kits, as well as the early discussion of antivirals and possible vaccines.

Read more: We Will Share Our Vaccine with the World. Inside the Chinese Biotech Firm Leading the Fight Against COVID-19

Zhang, 55, is keen to downplay the bravery of his actions. But the stakes of doing what is right over what one is told are rendered far higher in authoritarian systems like Chinas. Several whistleblower doctors were detained early in the pandemic. According to a Jan. 3 order seen by respected Beijing-based finance magazine Caixin, Chinas National Health Commission, the nations top health authority, forbade the publishing of any information regarding the Wuhan disease, while labs were told to destroy or transfer all viral samples to designated testing institutions. Caixin also reports that other labs had processed genome sequences before Zhang obtained his sample. None were published.

Its difficult to know what conclusions to draw. Dr. Dale Fisher, head of infectious diseases at Singapores National University Hospital, says he doesnt think that any delay by the Chinese authorities was malicious. It was more like appropriate verification, he says. Fisher traveled to China as part of a World Health Organization (WHO) delegation in early February and says outbreak settings are always confusing and chaotic with people unsure what to believe. To actually have the whole genome sequence by early January was outstanding compared to outbreaks of the past.

Of course, Zhangs fears based on the viral genome were just one evidence strut to inform Chinas decision-making process, alongside public health data and clinical reports about specific cases. Despite mounting evidence of human-to-human transmission, including doctors falling ill, it was only on Jan. 20 that China officially confirmed community transmission. Two days later, Wuhans 11 million residents were placed on a bruising lockdown that would last for 76 days. Even while the WHO publicly praised China for transparency, internal documents seen by the Associated Press suggest health officials were privately frustrated by the slow release of information. One joint study by scientists in China, the U.K. and U.S. suggests there would have been 95% fewer cases in China had lockdown measures been introduced three weeks earlier. Two weeks earlier, 86% fewer; one week, 66% fewer.

Read more: I Told Myself to Stay Calm. As Wuhans Lockdown Ends, A Doctor Recalls Fighting Coronavirus on the Front Line

Yet there was some historical basis for skepticism about the severity of the emerging viral disease. After all, the last global pandemicthe swine flu outbreak of 2009was far less deadly than initially feared, mainly because many older people had some immunity to the virus, leading to criticism that the WHO was overly hasty and even overly dramatic in declaring a pandemic when the virology didnt warrant it. In China, even though we had a very bad experience with SARS and other diseases, in the beginning nobodynot even experts from Chinas CDC and the Ministry of Healthpredicted the disease could be quite so bad, says Zhang.

Donald Trump disagrees. He has repeatedly claimed that swifter action by China could have stopped the pandemic in its tracks. The virus came from China, Trump said Aug. 10. Its Chinas fault. Beijing concedes that mistakes were made at the outset, though insists that blame lies solely with bungling local officials (who have since been punished for those failures), while the central governments response was exemplary. This is, of course, its own politically motivated oversimplification. On both sides, wild accusations have eclipsed reason as Sino-U.S. relations spiral to an unprecedented nadir. While U.S. officials have suggested that COVD-19 originated in a Wuhan laboratory, their Chinese counterparts have propagated conspiracy theories that the U.S. military is responsible. Its not a good thing for China and the U.S. to be involved in this struggle, says Zhang. If we cant work together, we cant solve anything.

Read more: The Coronavirus Outbreak Could Derail Xi Jinpings Dreams of a Chinese Century

Some facts are undeniable. The first U.S. case was confirmed on Jan. 21a man in his 30s who had just returned from Wuhan to his hometown in Washington State. Japan confirmed its first coronavirus case one day later, and reported the worlds highest infection number early in the outbreak, before getting a handle on the situation. Today, the U.S. has 16,407 cases per million population compared with 462 in Japan. Across the world, authoritarian and democratic nations have both handled the crisis well and poorly.

For its part, the global scientific community has risen to the challenge, working across national boundaries to advance understanding of the disease, including priceless collaborations between Chinese and Western virologists. Previously, the best described epidemic in terms of viral genetics was the 2014 West African Ebola outbreak. Then, about 1,600 genomes were mapped over three years, providing insights into how viruses move between locations and accumulate genetic differences as they do. But for SARS-CoV-2, following Zhangs initial genome, scientists mapped about 20,000 within three months. Genomic surveillance enables scientists to trace the speed and character of genetic changes, with ramifications for infection rates and the production of vaccines and antivirals. Very large-scale genomic screening can evaluate whether any resistance mutations have occurred and, if they do, how those spread through time, says Oliver Prybus, professor of evolution and infectious disease at Oxford University.

For Zhang, focus must now be on understanding how pathogens and the environment interact. Over the past century, an inordinate number of new viral diseases have emerged in China, including the 1956 Asian Flu, 2002 SARS and 2013 H7N9. Zhang attributes this to Chinas diverse ecology and enormous population. Moreover, as Chinas economy boomed its people have begun traveling far and wide in search of work, education and opportunities. According to the World Bank, almost 200 million people moved to urban areas in East Asia during the first decade of the 21st century. In China, 61% of the population lived in urban areas in 2020 compared with just 18% in 1978. This brings unknown pathogens and people without natural defenses into close proximity. People and pathogens must be in contact [for outbreaks], says Zhang. If no contact, no disease.

As urbanization intensifies, outbreaks of pathogenic diseases will only become more common. Mitigation, says Zhang, comes from deeper understanding of viruses, so that we can accurately map and predict which are likely to spill over into human populations. Just as satellites have made forecasting weather patterns unerringly reliable, Zhang believes science holds the key to predicting viral outbreaks with similar accuracy as with which we now anticipate typhoons and tornadoes. If we dont learn lessons from this disease, says Zhang, humankind will suffer another.

For your security, we've sent a confirmation email to the address you entered. Click the link to confirm your subscription and begin receiving our newsletters. If you don't get the confirmation within 10 minutes, please check your spam folder.

Write to Charlie Campbell at charlie.campbell@time.com.

Read this article:
Zhang Yongzhen Speaks Out About Controversies Around His Work - TIME

In a study published in PNAS, researchers used conservation biology and genomics to discover that the New Guinea singing dog, thought to be extinct for 50 years, still thrives. Scientists found that the ancestral dog population still stealthily wanders in the Highlands of New Guinea. This finding opens new doors for protecting a remarkable creature that can teach biologists about human vocal learning. The New Guinea singing dog can also be utilized as a valuable and unique animal model for studying how human vocal disorders arise and finding potential treatment opportunities. The study was performed by researchers at the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, Cenderawasih University in Indonesia, and other academic centers.

A female New Guinea singing dog sings at the San Diego zoo. Credit: San Diego Zoo

The New Guinea singing dog was first studied in 1897, and became known for their unique and characteristic vocalization, able to make pleasing and harmonic sounds with tonal quality. Only 200-300 captive New Guinea singing dogs exist in conservation centers, with none seen in the wild since the 1970s.

"The New Guinea singing dog that we know of today is a breed that was basically created by people," said Elaine Ostrander, Ph.D., NIH Distinguished Investigator and senior author of the paper. "Eight were brought to the United States from the Highlands of New Guinea and bred with each other to create this group."

According to Dr. Ostrander, a large amount of inbreeding within captive New Guinea singing dogs changed their genomic makeup by reducing the variation in the group's DNA. Such inbreeding is why the captive New Guinea singing dogs have most likely lost a large number of genomic variants that existed in their wild counterparts.This lack of genomic variation threatens the survival of captive New Guinea singing dogs. Their origins, until recently, had remained a mystery.

Another New Guinea dog breed found in the wild, called the Highland Wild Dog, has a strikingly similar physical appearance to the New Guinea singing dogs. Considered to be the rarest and most ancient dog-like animal in existence, Highland Wild Dogs are even older than the New Guinea singing dogs.

Researchers previously hypothesized that the Highland Wild Dog might be the predecessor to captive New Guinea singing dogs, but the reclusive nature of the Highland Wild Dog and lack of genomic information made it difficult to test the theory.

In 2016, in collaboration with the University of Papua, the New Guinea Highland Wild Dog Foundation led an expedition to Puncak Jaya, a mountain summit in Papua, Indonesia. They reported 15 Highland Wild Dogs near the Grasberg Mine, the largest gold mine in the world.

A follow-up field study in 2018 allowed researchers to collect blood samples from three Highland Wild Dogs in their natural environment as well as demographic, physiological and behavioral data.

NHGRI staff scientist Heidi Parker, Ph.D., led the genomic analyses, comparing the DNA from captive New Guinea singing dogs and Highland Wild Dogs.

"We found that New Guinea singing dogs and the Highland Wild Dogs have very similar genome sequences, much closer to each other than to any other canid known. In the tree of life, this makes them much more related to each other than modern breeds such as German shepherd or bassett hound," Dr. Parker said.

According to the researchers, the New Guinea singing dogs and the Highland Wild Dogs do not have identical genomes because of their physical separation for several decades and due to the inbreeding among captive New Guinea singing dogsnot because they are different breeds.

In fact, the researchers suggest that the vast genomic similarities between the New Guinea singing dogs and the Highland Wild Dogs indicate that Highland Wild Dogs are the wild and original New Guinea singing dog population. Hence, despite different names, they are, in essence, the same breed, proving that the original New Guinea singing dog population are not extinct in the wild.

The researchers believe that because the Highland Wild Dogs contain genome sequences that were lost in the captive New Guinea singing dogs, breeding some of the Highland Wild Dogs with the New Guinea singing dogs in conservation centers will help generate a true New Guinea singing dogs population.In doing so, conservation biologists may be able to help preserve the original breed by expanding the numbers of New Guinea singing dogs.

"This kind of work is only possible because of NHGRI's commitment to promoting comparative genomics, which allows researchers to compare the genome sequences of the Highland Wild Dog to that of a dozen other canid species," Dr. Ostrander said.

Although New Guinea singing dogs and Highland Wild Dogs are a part of the dog speciesCanis lupus familiaris, researchers found that each contain genomic variants across their genomes that do not exist in other dogs that we know today.

"By getting to know these ancient, proto-dogs more, we will learn new facts about modern dog breeds and the history of dog domestication," Dr. Ostrander said. "After all, so much of what we learn about dogs reflects back on humans."

The researchers also aim to study New Guinea singing dogs in greater detail to learn more about the genomics underlying vocalization (a field that, to date, heavily relies on birdsong data). Since humans are biologically closer to dogs than birds, researchers hope to study New Guinea singing dogs to gain a more accurate insight into how vocalization and its deficits occur, and the genomic underpinnings that could lead to future treatments for human patients.

Read more:
Scientists use genomics to discover ancient dog species that may teach us about human vocalization - National Human Genome Research Institute

MarketsandResearch.biz has published the latest market research study on Global Single-Cell Genome Sequencing Technology Market 2020 by Company, Regions, Type and Application, Forecast to 2025 which investigates a few critical features of the market such as industry condition, division examination, market insights. The report studies the global Single-Cell Genome Sequencing Technology market share, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels. The report has referenced down to earth ideas of the market in a straightforward and unassuming way in this report. The research contains the categorization of the market by top players/brands, region, type, and end-user. The report exhaustive essential investigation of current market trends, opportunities, challenges, and detailed competitive analysis of the industry players in the market.

The research report has comprehensively included numbers and figures with the help of graphical and pictorial representation which embodies more clarity on the global Single-Cell Genome Sequencing Technology market. Then the report delivers key information about market players such as company overview, total revenue (financials), market potential, global presence, as well as market share, prices, production sites and facilities, products offered, and strategies adopted by them. Market status and outlook of global and major regions, from angles of players, countries, product types, and end industries have been analyzed.

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/82006

Key strategic manufacturers included in this report: Fludigim, Oxford Nanopore Technologies, F Hoffmann-La Roche Ltd., QIAGEN, 10X Genomics, Inc., Illumina, Pacific Biosciences, Bio-Rad, Thermo Fisher Scientific, Inc., BGI, Tecan Group, Novogene Co. Ltd., Takara Bio, Inc.

Market Potential:

Key market vendors have been predicted to obtain the latest opportunities as there has been an increased emphasis on spending more on the work of research and development by many of the manufacturing companies. Also, many of the market contenders are forecasted to make a foray into the emerging economies to find new opportunities. The global Single-Cell Genome Sequencing Technology market has gone through rapid business transformation by good customer relationships, drastic and competitive growth, significant changes within the market, and technological advancement in this market.

Geographically, this report is segmented into several key countries, with market size, growth rate, import and export of in these countries from 2015 to 2020, which covering: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), MENA (Saudi Arabia, UAE, Turkey and South Africa)

The market can be segmented into product types as: NGS, PCR, qPCR, Microarray, MDA

The market can be segmented into applications as: Academic and research laboratories, Biotechnology and biopharmaceutical companies, Clinics, Others

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/82006/global-single-cell-genome-sequencing-technology-market-2020-by-company-regions-type-and-application-forecast-to-2025

Reasons for Buying Market Report:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketsandresearch.biz

Here is the original post:
Global Single-Cell Genome Sequencing Technology Market 2020 Analysis, Types, Applications, Forecast and COVID-19 Impact Analysis 2025 - Scientect

The COVID-19 pandemic has dramatically demonstrated humankinds vulnerability towards infectious diseases especially with the lack of a vaccine or drug to treat the infections.

Luckily, for many infectious diseases caused by bacterial pathogens, we have efficient drugs antibiotics to treat them. However, for these diseases there is also an alarming trend: Increasing numbers of pathogenic bacteria have acquired antimicrobial resistance, which renders many antibiotics useless and makes formerly easily treatable infections life-threatening or even deadly. Currently, more than 700,000 people die each year due to drug-resistant diseases, including 230,000 people who die from multidrug-resistant tuberculosis, according to the UN.

One important pillar of addressing this severe global challenge is the development of novel antimicrobials. But industrial pipelines are almost empty when it comes to new classes of antibiotics. To understand why, we need to look back.

Historically, most antimicrobials originate from bacterial or fungal microorganisms. Especially in the 1950s and 1960s, the antimicrobial drug discovery field experienced a golden age with many of the current antibiotics being discovered and developed. Starting in the 1970s, however, there was a huge decline in industrial antibiotic development. With many antibiotics running off-patent, the prices for antibiotic therapies dropped significantly, reducing commercial interest in the whole antibiotics development market. Also, there were scientific challenges: In the large-scale screening campaigns of the 1950-70s, most of the low-hanging fruits were picked. New antibiotics were essentially too hard to find and develop compared to the pay-off.

The situation is more or less the same today. But because of antimicrobial resistance and new genome sequencing methods, the field is slowly opening up once more. Instead of solely relying on isolating and characterising the chemicals from bacteria that can grow in a petri dish, researchers turn to Genome Mining. With this approach, identifying so-called biosynthetic gene clusters (BGCs) of potential producing organisms has become feasible. This trend is strongly supported by the parallel development of powerful bioinformatics software that helps scientists in this task. For ten years, scientists of DTU Biosustain have been developing such tools, for example the widely used antiSMASH platform (see box).

Identifying interesting pathways is only the first step: often BGCs encoding a potentially novel compound are not expressed under laboratory conditions; the expression needs triggering. While expression is still a challenge, new CRISPR-based genetic engineering technologies to engineer the producer strains as well as methods to move BGCs from poorly studied organisms into optimized cellular workhorses help us to get back in business, so to speak.

The different technologies developed at DTU Biosustain are integrated into the international project Integration of informatics and metabolic engineering for the discovery of novel antibiotics (iimena), which is funded by a Challenge Grant by the Novo Nordisk Foundation. Scientists from DTU Biosustain work together with the Korea Advanced Institute of Science and Technology (KAIST) and the Fundacin MEDINA Centro de Excelencia en Investigacin de Medicamentos Innovadores en Andaluca. The iimena project integrates BGC discovery with innovative high throughput screening, adaptive laboratory evolution and metabolic engineering technologies. In short: we are using all the newest technologies available to tap into the secret world of active compounds produced by bacteria and fungi to reveal the next generation of antibiotics. And with the access to MEDINAs unique strain collection, we expect to find multiple new antibiotic drug candidates.

Since the project started in late 2017, iimena scientists have contributed to various key technologies, such as the antiSMASH platform (Blin, K., et al., 2019, Nucleic Acids Res. 47:W81-W87, Blin, K., et al., 2019, Nucleic Acids Res. 47:D625-D630), CRISPR-tools (Tong, Y., et al., 2020, Nat. Prot. 15:2470-2502, Tong, Y., et al., 2019, PNAS 116:20366-20375), precursor-biosensors (Yang, D., et al., 2018, PNAS 115:9835-9844), which already now are used by many laboratories world-wide.

The worlds of big data, software, and wet lab biology merge together these days. DTU Biosustain just recently received a 100 million extension grant from the Novo Nordisk Foundation to continue its activities for the next five years. A large proportion of this grant will go into developing software tools for the discovery of sustainable medical compounds, food, and chemicals. iimena speaks directly into this scope, and the synergies are obvious.

The iimena project will run for further 2.5 years and aims in addition to developing core technologies to find five new antibiotic candidates. But it does not stop there: The need for more research and more drug candidates in the antibiotics pipeline is urgent. The problem of antimicrobial resistance does not go away it only gets worse, so we need to act now.

The Open Source genome mining platform antiSMASH is the most widely used bioinformatics software to mine microbial genome sequences for secondary metabolite BGCs. More than 750,000 analysis runs have been computed on the publicly webserver hosted by DTU. antiSMASH is a joint development, currently maintained by T. Weber/K.Blin at DTU Biosustain and M. Medema at Wageningen University, with contributions by dozens of leading scientists working in the field. The software offers an easy access to the genetic potential of microbes to synthesize natural products without requiring dedicated bioinformatics skills. The platform also integrates a database of biosynthetic gene clusters, and the MIBiG repository of experimentally determined and validated gene clusters.

Please note: This is a commercial profile

Editor's Recommended Articles

Go here to read the rest:
Finding new antibiotics: The genome way - Open Access Government

Genome sequencing mapping the genetic sequences of the virus from confirmed COVID-19 cases in a bid to track its spread is now an integral part of New Zealands coronavirus response. It is providing greater certainty in identifying clusters and helps focus the investigations of contact tracers.

In contrast to the first outbreak, during which only 25 of the more than 1,000 positive samples had been genetically sequenced by mid-April, genome sequencing results are now available overnight, and sometimes even on the same day. This allows health authorities to infer a connection between cases or pinpoint potential sources of infection much more promptly than before.

So far, the technique has confirmed Aucklands second wave of cases are all part of the same cluster, except for one case identified on Tuesday who contracted the virus via exposure to a returned traveller from the United States.

But despite our rapidly improving knowledge, we still dont know how and where the current outbreak started.

Genome Sequencing Proves Useful to Understand the Cluster

There are now 87 confirmed cases in the new Auckland cluster. All are in quarantine, along with some of their close contacts.

The sequencing technology has shown its value in three distinct ways since this new outbreak was confirmed last week.

First, it identified a new case without links to the current community cluster. A maintenance worker at the Rydges Hotel managed isolation facility tested positive on Sunday. By Tuesday, sequencing results showed this case was not part of the wider cluster, but rather that the genetic sequences matched those from a US returnee who had stayed at the Rydges before testing positive and being moved into quarantine.

Without rapid genome sequencing, contact tracers would have spent considerable effort looking for a link to the known cluster. Instead, their work is now focused on finding out how the worker got infected and whether there are any intermediate cases.

Second, genome sequencing has also shown that all other cases so far are part of a single cluster. This was mostly expected based on established physical links, but the genetic confirmation is nevertheless valuable.

Contact tracing casts a broad net. If a known case has visited a school, church or large workplace, many hundreds of people may need to be tested. Genomic evidence can tell us whether any of those contacts who subsequently test positive are indeed part of the same cluster, or whether they were infected elsewhere. When we look back at the first wave of infections, several of the cases that were assigned to the same cluster were shown not to be genetically related after all, showing contact tracing alone is not fail-safe.

Third, there were a few cases for which contact tracing produced only uncertain links between people, but sequencing confirmed they were part of the same cluster.

Looking for a Source

So far, genomics has given us a lot of valuable information about New Zealands current round of infections. But it hasnt established the ultimate source of this second-wave outbreak. However, it has yielded some clues.

It indicates the current cluster comes from the so-called B.1.1.1 lineage, most frequently documented in the UK but more recently found in Europe, Australia and South Africa. This lineage has been seen once before in New Zealand, in a pair of cases in mid-April who were in managed isolation in Auckland.

This points to two possible scenarios. Either the second wave is due to a recent border incursion from a country where this viral lineage has been transmitted. Or, alternatively, it is the result of ongoing transmission in New Zealand starting from the pair identified in April.

Lets tackle each in turn, starting with the recent border incursion theory.

The virus can be transmitted in managed isolation facilities, as the recent Rydges hotel case underlines. Around 40% of cases found in managed facilities have no available genome sequence because the sample contains too little viral material. This usually indicates a low viral load (and low level of infectiousness), but it does not rule out transmission. The source may be among one of these cases.

Neither can we rule out the possibility that a case in managed isolation or elsewhere at the border was not detected. Even testing twice (currently on days three and 12 of quarantine) is expected to miss at least 4% of cases, based on a false negative rate that is at best 20%. This high false negative rate is one reason to insist on 14 days of isolation.

Next, lets look at the possibility of ongoing transmission in NZ since the first outbreak. With a close genomic match found, we cant completely dismiss this possibility. But the theory also depends on some unlikely assumptions: that the infection leaked from managed isolation, was transmitted undetected for about 15 generations until finally being found, and mutated fairly slowly over that period.

This sounds very unlike the virulent, fast-spreading virus we think we know, although its also true the initial stages of growth of an outbreak can be slow.

Ideally, we would accurately calculate the likelihood of each scenario. But even so, recent transmission across the border is clearly more likely, given the presence of this strain around the world and the absence of any intermediate cases to link NZs first and second waves.

Even trying to determine the country of origin is hard. Many lineages, including B.1.1.1, have a wide global spread. We can understand the extent of the spread using GISAID, the global database in which viral genomes are shared. But with different countries having radically different sequencing efforts (of the 81,000 genomes on GISAID, 35,000 are from the UK alone), finding a link to a country could merely indicate that country has done lots of sequencing. An approach that combines genomic data with data on all international arrivals could be more fruitful.

Whatever the source, we can take heart in New Zealands response to this first known community transmission since the original epidemic. New systems to understand the epidemic have swung into action and quickly proved their worth.

Sequencing of viral genomes has become part of the pipeline to aid contact tracing. The resulting sequences will be useful to science well beyond the immediate response, as we seek to develop a deeper understanding of this virus, and epidemics more generally.

David Welch, Senior lecturer

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Image: Reuters

Visit link:
What Genome Sequencing Can Tell Us About Auckland Coronavirus Outbreak - The National Interest

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the human microbiome therapeutics market and it is poised to grow by USD 276.93 mn during 2020-2024, progressing at a CAGR of almost 15% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. Download a Free Sample Report on COVID-19 Impacts

Frequently Asked Questions:

The market is concentrated, and the degree of concentration will accelerate during the forecast period. Bristol-Myers Squibb Co., Dow Inc., ENTEROME SA, Ferring Pharmaceuticals AS, Johnson & Johnson, Kaleido Biosciences Inc., PureTech Health Plc, Second Genome Therapeutics, Seres Therapeutics Inc., and Takeda Pharmaceutical Co. Ltd. are some of the major market participants. The growing prevalence of chronic diseases will offer immense growth opportunities. To make most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations.

Human Microbiome Therapeutics Market 2020-2024: Segmentation

Human Microbiome Therapeutics Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43730

Human Microbiome Therapeutics Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The human microbiome therapeutics market report covers the following areas:

This study identifies growing investments from venture capitalists as one of the prime reasons driving the human microbiome therapeutics market growth during the next few years.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Human Microbiome Therapeutics Market 2020-2024: Key Highlights

Table of Contents:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Application

Customer landscape

Geographic Landscape

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Read the original here:
Human Microbiome Therapeutics Market Analysis Highlights the Impact of COVID-19 (2020-2024) | Growing Prevalence of Chronic Diseases to Boost the...

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Global Single Cell Genome Sequencing Market Report that covers exclusive and analytical data through the span of seven years between 2020-2026. This report is exclusive and encompasses in-depth analysis and industry insights on Global Single Cell Genome Sequencing Market. What you will get by reading the report is not just charts, bars, analytical data but also a better understanding of the market which will in turn help you make decisions in the better interest of your organisation.

FREE Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2059

Single Cell Genome Sequencing Market report provides key statistics on the market status of the Single Cell Genome Sequencing manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. The report also presents the vendor landscape and a corresponding detailed analysis of the major vendors operating in the market.

Highlights of The Single Cell Genome Sequencing Report:

How Will The Single Cell Genome Sequencing Market Report Be Beneficial?

This report will be a valuable assessment for new startups who wish to enter the Global Single Cell Genome Sequencing Market, as it will not just provide the current market trends but also predict the future trends. You will get a look at the customised market segments according to geographical regions, country or even different combinations of manufacturers in the market.

Major Players in the Single Cell Genome Sequencing Market: Illumina, Inc., Fludigim Corporation, Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd., Inc., QIAGEN, Bio-Rad Laboratories, 10x Genomics, Novogene, BGI, Oxford Nanopore Technologies, and Pacific Biosciences

Geographical Base of Single Cell Genome Sequencing Market:

The study objectives of Single Cell Genome Sequencing Market report are:

Click To get FREE PDF Of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2059

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah, Coherent Market Insights1001 4th Ave, #3200, Seattle, WA 98154, Tel: +1-206-701-6702Email: [emailprotected]

Excerpt from:
Single Cell Genome Sequencing Market: Analysis of Prevailing Trends In The Parent Market 2026 - Scientect

Health technology is a rapidly growing industry, and I dont think I need to explain why. Just look around you. Here we are, six months into a pandemic with little improvement in sight. How is there not a reliable treatment for COVID-19 yet? With over 24 million cases worldwide, how will the eventual vaccine be able to effectively immunize the whole world when there are still treatments for diseases from outbreaks past that dont work for many patients?

Our Startup of the Week, 54gene ($54GENE), has some answers. According to 54gene, the African genome is the most genetically diverse than all others in the world combined, yet makes up for only 3% of the data used for research and development of medicines and treatments.

At a BusinessDay panel in March, CEO Abasi Ene-Obong described the problem which 54gene addresses. Twenty-five percent of Africans cannot metabolize [a certain HIV drug], he said. Why is that? Because when that drug is being discovered and being trialed, the drug companies did not look at Africans.

By increasing access to this deep well of information, 54gene hopes to help create better medical solutions.

Thats a pitch that has investors quickly hopping aboard. 54gene is a very young company, only founded in 2019. In that short time, the company raised $4.5 million in a seed round and $15 million in Series A. With a massive pool of data at its fingertips that could have major consequences on global medicine, 54gene is the philosopher in Platos Cave, returned to a small world stuck in its ways armed with a universe of possibilities.

54genes growth shows the scale of the opportunity it has tapped into. In 2020 alone, the Lagos and Washington-based companys workforce has grown by 81 employees - a 225% increase in just six months. 54gene has managed to grow to a size that many startups take years to achieve in a fraction of the time.

54genes timing was impeccable. Breaking into the scene just before COVID-19 became a pandemic, 54gene was prepared with a solution to many of the concerns now facing the medical community. It is already involved in testing services and offers a mountain of data that could help with development of vaccines and treatments, making it easy to see why investors have quickly taken to the young company.

CEO Abasi Ene-Obong is refreshingly honest about the company goals as well. The cliche of the startup that says its making the world a better place is real and rampant, and 54gene sets itself apart by actually offering something that could positively impact the lives of patients across the planet, and by being clear about its goals as a profit-driven company.

I think [people invested in us] because they understood the potential for good. But one of the things Id like to say is that impact investment is not the same as charity, Ene-Obong said. As a company founder and CEO, I want to make money. I want to be profitable. That is one of the metrics Ill judge myself by. But at the same time, I want to do good.

Ene-Obong and 54gene are certainly on their way to accomplishing both. It is one of the fastest-growing health disruptors in the world, and has the potential to make waves across the healthcare industry on a global scale. Years down the road, you may find yourself taking a treatment and experiencing no side effects. It may be thanks to 54gene that you end up giving it little to no thought.

Continued here:
Startup of the Week: 54gene is bringing medicine out of the dark ages - Thinknum Media

A woman who was infected with H.I.V. in 1992 may be the first person cured of the virus without a risky bone-marrow transplant or even medications, researchers reported on Wednesday.

In an additional 63 people in their study who controlled the infection without drugs, H.I.V. apparently was sequestered in the body in such a way that it could not reproduce, the scientists also reported. The finding suggested that these people may have achieved a functional cure.

The research, published in the journal Nature, outlines a new mechanism by which the body may suppress H.I.V., visible only now because of advances in genetics. The study also offers hope that some small number of infected people who have taken antiretroviral therapy for many years may similarly be able to suppress the virus and stop taking the drugs, which can exact a toll on the body.

It does suggest that treatment itself can cure people, which goes against all the dogma, said Dr. Steve Deeks, an AIDS expert at the University of California, San Francisco, and an author of the new study.

The woman is Loreen Willenberg, 66, of California, already famous among researchers because her body has suppressed the virus for decades after verified infection. Only two other people Timothy Brown of Palm Springs, Calif., and Adam Castillejo of London have been declared cured of H.I.V. Both men underwent grueling bone-marrow transplants for cancer that left them with immune systems resistant to the virus.

Bone-marrow transplants are too risky to be an option for most people infected with H.I.V., but the recoveries raised hopes that a cure was possible. In May, researchers in Brazil reported that a combination of H.I.V. treatments may have led to another cure, but other experts said more tests were needed to confirm that finding.

I think that is a novel, an important discovery, Dr. Sharon Lewin, director of the Peter Doherty Institute for Infection and Immunity in Melbourne, said of the new study. The real challenge, of course, is how you can intervene to make this relevant to the 37 million people living with H.I.V.

Even among viruses, H.I.V. is particularly wily and difficult to eradicate. It inserts itself into the human genome and tricks the cells machinery into making copies. H.I.V. naturally prefers to lurk within genes, the most active targets of the cells copiers.

In some people, the immune system over time hunts down cells in which the virus has occupied the genome. But intensive scrutiny of the participants in this study showed that viral genes may be marooned in certain blocked and locked regions of the genome, where reproduction cannot occur, said Dr. Xu Yu, the studys senior author and a researcher at the Ragon Institute in Boston.

The participants in the research were so-called elite controllers, the 1 percent of people with H.I.V. who can keep the virus in check without antiretroviral drugs.

It is possible that some people who take antiretroviral therapy for years may also arrive at the same outcome, especially if given treatments that can boost the immune system, the researchers speculated.

This unique group of individuals provided to me sort of a proof of concept that it is possible with the host immune response to achieve what is really, clinically, a cure, Dr. Deeks said.

Elite controllers have been exhaustively studied for clues to how to control H.I.V. Ms. Willenberg has been enrolled in such studies for more than 15 years. With the exception of one test years ago that indicated a small amount of virus, researchers were never able to identify H.I.V. in her tissues.

In the new study, Dr. Yu and her colleagues analyzed 1.5 billion blood cells from Ms. Willenberg and found no trace of the virus, even using sophisticated new techniques that can pinpoint the viruss location within the genome.

Millions of cells from the gut, rectum and intestine also turned up no signs of the virus.

She could be added to the list of what I think is a cure, through a very different path, Dr. Lewin said.

Other researchers were more circumspect. Its certainly encouraging, but speculative, said Dr. Una ODoherty, a virologist at the University of Pennsylvania. I need to see more before I would say, Oh, shes cured.

But Dr. ODoherty, an expert in analyzing large volumes of cells, said she was impressed by the results overall.

Another 11 people in the study, whom the researchers referred to as exceptional controllers, have the virus only in a part of the genome so dense and remote that the cells machinery cannot replicate it.

Some people who suppress the virus without drugs dont have detectable antibodies or immune cells that rapidly respond to H.I.V. But their immune systems carry a potent memory of the virus, the team found.

Powerful T cells, a constituent of the immune system, eliminated cells in which the viral genes had lodged in more accessible parts of the genome. The infected cells that remained held the virus only in remote regions of the genome where it could not be copied.

Thats really the only explanation for the findings we have, said Dr. Bruce Walker, a researcher at the Ragon Institute who has studied elite controllers for 30 years.

About 10 percent of people who take antiretroviral treatments, especially those who start doing so soon after being infected, also successfully suppress the virus even after they stop taking the drugs. Perhaps something similar is at work in those people as well, experts suggested.

H.I.V. cure studies have focused on rooting out all of the virus thats hidden in the genome. The new study offers a more attainable solution: If the virus remains in only parts of the genome where it cannot be reproduced, the patient may still achieve a functional cure.

The part thats in the gene deserts just doesnt matter, Dr. Walker said. It suggests that as were doing these studies, we need to not just be looking at quantity of the reservoir, but we really need to look at quality.

Since the researchers completed the study, they have analyzed samples from 40 elite controllers and have found a couple more that could qualify as cures, Dr. Yu said: We believe theres definitely many of them out there.

With help from Dr. Deeks, they are contacting people with H.I.V. who have taken antiretroviral drugs for 20 years or more and who may have managed to banish the virus to the deserts of their genomes.

Antiretroviral drugs can have harsh side effects, including heart disease and organ damage, especially when taken over many years. A functional cure, if it is borne out by further research, would transform patients lives, Dr. Yu said: They can stop their treatment and can be just cured, to be healthy for the rest of their life.

Read more:
A Woman May Have Been Cured of H.I.V. Without Medical Treatment - The New York Times

The Australian government needs to develop a bold vision and strategic plan to create the data-driven healthcare system and bioeconomy of the future.

In my new report for ASPI, Biodata and biotechnology: Opportunity and challenges for Australia, I explain how the extraordinary developments in genome sequencing and genetic engineering will transform all biological enterprises, especially healthcare, and create new ones, like the electronic revolution. I explain why Australia should harness and capitalise on our high-quality biomedical science, agricultural research and development, and healthcare systems to realise a once-in-a-generation opportunity to play a leading role in a major economic revolution.

Biotechnology dates back over 6,000years to the domestication of wheat and the use of yeast for fermentation, but has entered the province of human design and invention as a consequence of the gene-cloning, gene-manipulation and genome-sequencing revolutions of the past 50years.

While often thought of in terms of drug development and genetic engineering, biotechnology is fundamentally becoming an information industry with a universe of applications.

Humans have acquired the ability to read the genetic programming and analyse the structure of the molecules of lifehow cells work, how were different from each other, and what makes a lime different from a lemon. Life has evolved the most exquisite nanomachinesprotein machines that can bind oxygen and almost any other type of molecule; trap photons to turn carbon dioxide and water into carbohydrates; detect electric fields or sound waves and turn them into visual images; pump ions; facilitate the entry of viruses, bacteria and parasites into cells; and make molecular motors that spin or contract to trap prey, exert force and move.

The extraordinary advances in DNA sequencing are leading to an avalanche of genomic information. Genetic engineering can now be done with high speed and precision. The pace of change is accelerating, and biological technologies are intersecting with optical technologies, nanotechnologies, advanced computing and artificial intelligence to create possibilities that were, if not beyond imagination, well beyond feasibility just a few years ago.

The advent of population-scale genomic and smart sensor data will transform health care, health economics, medical research and drug development. It will also transform the national economy and create digital products that can be exported to the world. To achieve this, the Australian government needs a strategic plan for acquiring genomic, clinical, pharmaceutical, sensor and patient self-reporting data and for providing trusted online evidence-based analysis of that information and advice to healthcare practitioners and citizens.

Governments also need to convince citizens of the personal and national value of big data in health care, and the privacy and security of that data, using a model that combines political leadership with subject-matter expertise.

The Australian government should establish a secure national repository for genomic and phenotypic data for research and healthcare use. This de-identified data should be made available to Australian researchers and health system managers. It could be provided to external parties, such as pharmaceutical companies, under appropriate conditions in exchange for early access to expensive treatments or shared benefits.

The Australian government should establish a central unit to assemble and supply evidence-based, well-curated and continuously updated genomic analysis, integrated with clinical and other data, and linked to national treatment guidelines, for decision support at the point of care.

The cost of doing this will be trivial compared with other costs in the healthcare system, and trivial in relation to the cost reductions and healthcare improvements that it will enable. This work could be funded from the Medical Research Future Fund and publicprivate partnerships.

Smart sensors should be made available through Medicare and routinely installed in hospitals, clinics and other healthcare settings, such as aged-care homes.

Conversion to electronic health records should be mandatory for all healthcare providers receiving government support or reimbursement in Australia, as recommended by the Australian Academy of Technology and Engineering.

Genetic tests should be progressively upgraded to whole-genome sequencing to build the national genomic estate. That would convert diagnostic expenses into an enduring strategic asset.

All suitably accredited health professionals, including general practitioners, should be able to obtain a genomic report, pharmacogenomic advice, early warning of an incipient disease, or any combination of that information, about a patient (with patient approval) upon request, and bulletins issued where relevant. Citizens should also be entitled to access such information in the interests of caring for their own health, provided it is conservative and actionable.

Security and police agencies should establish internal expertise in biotechnology and biodata analysis. They should have access to national genomic information under defined circumstances and subject to judicial approval and oversight.

Major investment funds and relevant government departments should consider establishing bio-intelligence units to keep abreast of opportunities and incorporate those opportunities into their strategic planning. Australian research funding agencies and the CSIRO should continue to invest in advanced genetic engineering and vaccine and drug development. Superannuation funds should be encouraged to invest at least 1% of their resources into domestic start-up and early-phase high-tech and digital enterprises, especially in health and biotechnologies.

Universities should provide training in computer programming and big-data analysis as a core component of all science and engineering degrees.

More:
Australia can take the lead in biotechnology revolution | The Strategist - The Strategist